Gentris Corp.
This article was originally published in Start Up
Executive Summary
Gentris Corp. is developing and commercializing proprietary clinical pharmacogenomic markers, initially for pharmaceutical customers but ultimately to offer as clinical diagnostics. Pharmacogenomics, it believes, can improve trial design, and increase predictability, shorten the drug development cycle, improve new drug approval rates, and enable companies to retest drug candidates that fail to meet clinical trial or FDA approval standards.